National Institute of Allergy and Infectious Diseases (NIAID): Cytomegalovirus Infections trials

The registry lists 28 Cytomegalovirus Infections studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 5Phase 2 8Phase 3 5Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)CompletedNCT05099965Phase 2Results posted
• A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.TerminatedNCT04840199Phase 2Results posted
• Dried Blood Spot Testing of CMV Detection in HCT RecipientsCompletedNCT03910478Not applicableResults posted
• Asymptomatic Congenital CMV TreatmentTerminatedNCT03301415Phase 2Results posted
• Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing LossCompletedNCT01649869Phase 2Results posted
• CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")CompletedNCT01552369Phase 4Results posted
• Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV InfectionsCompletedNCT00466817Phase 3Results posted
• A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital CytomegalovirusCompletedNCT06118515Phase 1
• PREDICT Cytomegalovirus (CMV)CompletedNCT03300882
• Safety and PK of MBX-400 (Cyclopropavir) in Normal VolunteersCompletedNCT02454699Phase 1
• Cytomegalovirus Cell-Mediated ImmunityCompletedNCT00815165
• CMV Infection in Adolescent MalesTerminatedNCT00302029
• gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent FemalesCompletedNCT00133497Phase 2
• Valganciclovir in Congenital CMV InfantsCompletedNCT00031434Phase 1/2
• Neonatal CMV-Ganciclovir Follow-up StudyCompletedNCT00031421
• Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIVCompletedNCT00006145Phase 3
• A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) InfectionCompletedNCT00005572
• Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus InfectionCompletedNCT00001976
• A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.CompletedNCT00001100Phase 3
• A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected PatientsCompletedNCT00001089
• The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected PatientsCompletedNCT00001082Phase 3
• A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected PatientsCompletedNCT00001038Phase 3
• The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIVCompletedNCT00001034Phase 2
• A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) InfectionCompletedNCT00000995Not applicable
• The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDSCompletedNCT00000981Phase 2
• A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV TherapyCompletedNCT00000905
• A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) DiseaseWithdrawnNCT00000881Phase 1
• A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus DiseaseCompletedNCT00000805Phase 1